E3 ligase pathways for liver diseases, a trypanosome RPA1 inhibitor and more

Innovations captured last week in BioCentury’s Distillery, a curated database of translational academic research from over 25 journals, included two proteasomal degradation-regulating targets for chronic liver diseases, a small molecule therapy for African trypanosomiasis, and an mRNA vaccine with an NKT cell-activating adjuvant for malaria.

A team from Harbin Medical University in China showed promoting the activity of CAND1, a regulator of Cullin-RING E3 ubiquitin ligases, could help treat non-alcoholic fatty liver disease (NAFLD) by decreasing degradation of the fatty acid-oxidizing enzyme ACAA2...